Abstract

Background: Immunosuppressants or anti-inflammatory drugs was used in treatment of bowel disease. The aim of the present article was to evaluate the intestinal anti-inflammatory properties activity of resveratrol nanoemulsion (RENE) against ulcerative colitis induced by DSS in rats.

Results: RENE was prepared with size of 49.5 ± 0.05 nm and zeta potential of +15.75 with the observed shapes of nanoparticle was spherical. Also, RENE (39.75 mg/kg b.w.) was administered orally to DSS-induced colitic rats for 21 days

RENE (100 µM) significantly reduces in vitro the release of TGFB1 in the extracellular matrix of in human intestinal colorectal adenocarcinoma cell line and human colon carcinoma cell line HT29. The daily oral administration of the RENE at a concentration of 39.75 mg/kg body weight for 21 days to rats ameliorated the histological damage, body weight, DAI score, colon length and severity of DSS- induced colitis, and improved the compromised oxidative status of the colon. However, only the rats treated with RENE showed a significant reduction in the levels of different pro-inflammatory cytokines (TNF- α and MPO) and nitric oxide in comparison with the DSS control group. Moreover, RENE significantly decreases the gene expression of TGFB1 and IL-4 as well as significantly increases the gene expression of trefoil factor 3 (TFF3) in comparison with the DSS control group.

Conclusion: The results clearly suggest that RENE displayed intestinal anti-inflammatory properties in the DSS model of colitis in rats, which were improved by functionalization with the TGFB1, IL-4 and TFF3 gene expression.

Keywords: Resveratrol Nanoemulsion; DSS; Ulcerative Colitis; Colon Carcinoma; Nanoparticles Oxidative Stress Biomarkers and TFF3

References

1. Ghosh S and Mitchell R. “Impact of Inflammatory Bowel Disease on quality of life: Results of the European Federation of Crohn's and Ulcerative Colitis Associations (EFCCA) patient survey”. Journal of Crohn's and Colitis1 (2007): 10-20.
2. Creighton CJ., et al. “Molecular profiling uncovers a p53-associated role for microRNA-31 in inhibiting the proliferation of serous ovarian carcinomas and other cancers”. Cancer Research5 (2010): 1906-1915.
3. Danese S. “New therapies for inflammatory bowel disease: from the bench to the bedside”. GUT6 (2012): 918-932.
4. Solbers I., et al. “Clinical course in Crohn's disease: results of a Norwegian population-based ten-year follow-up study”. Clinical Gastroenterology and Hepatology 12 (2007): 1430-1438.
5. Evans P and Pardi DS. “Extraintestinal manifestations of inflammatory bowel disease: focus on the musculoskeletal, dermatologic, and ocular manifestations”. MedGenMed Gastroenterology1 (2007): 55.
6. Chong MM., et al. “The RNAseIII enzyme Drosha is critical in T cells for preventing lethal inflammatory disease”. Journal of Experimental Medicine9 (2007): 2005-2017.
7. Cobb BS., et al. “A role for Dicer in immune regulation”. Journal of Experimental Medicine11 (2006): 2519-2527.
8. Ceppi M., et al. “MicroRNA-155 modulates the interleukin-1 signaling pathway in activated human monocyte-derived dendritic cells”. Proceedings of the National Academy of Sciences of the United States of America 8 (2009): 2735-2740.
9. Allocca M., et al. “can il-23 be a good target for ulcerative colitis?” Best Practice and Research: Clinical Gastroenterology 32-33 (2018): 95-102.
10. Jeoung Br., et al. “Ganghwaljetongyeum, an anti-arthritic remedy, attenuates synoviocyte proliferation and reduces the production of proinflmmatory mediators in macrophages: The therapeutic effect of GHJTY on rheumatoid arthritis”. BMC Complementary Medicine and Therapies 13 (2013): 47.
11. Jeong HY., et al. “Anti‑inflmmatory activity of citric acid‑treated wheat germ extract in lipopolysaccharide-stimulated macrophages”. Nutrients 9 (2017).
12. Xiang Y., et al. “Brusatol inhibits growth and induces apoptosis in pancreatic cancer cells via JnK/p38 MaPK/nF-κb/Stat3/Bcl-2 signaling pathway”. Biochemical and Biophysical Research Communications 487 (2017): 820-826-13.
13. Xie Z., et al. “Hepatitis c virus nonstructural 5a protein (HcV-nS5a) inhibits hepatocyte apoptosis through the nF-κb/mir-503/bcl-2 pathway”. Molecular Cells 40 (2017): 202-210.
14. Eissa N., et al. “chromofungin (cHr: cHGa47-66) is downregulated in persons with active ulcerative colitis and suppresses pro‑inflmmatory macrophage function through the inhibition of nF-κB signaling”. Biochemical Pharmacology 145 (2017): 102-113.
15. Fuschiotti P. “Role of IL-13 in systemic sclerosis”. Cytokine 56 (2011): 544-549.
16. Mifflin RC., et al. “Intestinal myofibroblasts: targets for stem cell therapy”. American Journal of Physiology-Gastrointestinal and Liver Physiology 300 (2011): G684-G696.
17. Speca S., et al. “Cellular and molecular mechanisms of intestinal fibrosis”. World Journal of Gastroenterology 18 (2012): 3635-3661.
18. Roberts A B., et al. “Smad3: a key player in pathogenetic mechanisms dependent on TGF-beta”. Annals of the New York Academy of Sciences 995 (2003): 1-10.
19. Okayasu I., et al. “A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice”. Gastroenterology 98 (1990): 694-702.
20. Guerrero RF., et al. “Wine, resveratrol and health: A review”. Natural Product Communications 4 (2009): 635-658.
21. Baur JA., et al. “Therapeutic potential of resveratrol: The in vivo evidence”. Nature Reviews Drug Discovery 5 (2006): 493-506.
22. Hussien MA. “Prophylactic effect of resveratrol against Ethinylestradiol-Induced Liver Cholestasis”. Journal of Medicinal Food 3 (2013): 246-254.
23. Zhi Z., et al. “Polyphenols from Camellia sinenesis attenuate experimental cholestasis-induced liver fibrosis in rats”. American Journal of Physiology-Gastrointestinal and Liver Physiology 285 (2003): G1004-G1013.
24. Guerrero RF., et al. “Wine, resveratrol and health: A review”. Natural Product Communications 4 (2009): 635-658.
25. Baur JA and Sinclair DA. “Therapeutic potential of resveratrol: The in vivo evidence”. Nature Reviews Drug Discovery 5 (2006): 493-506.
26. Hussein MA. “A convenient mechanism for the free radical scavenging activity of resveratrol”. International Journal of Phytomedicine 3 (2011): 459-469.
27. Majid M., et al. “Comparison of effect of resveratrol and vanadium on diabetes related dyslipidemia and hyperglycemia in streptozotocin induced diabetic rats”. Advanced Pharmaceutical Bulletin 2 (2011): 81-86.
28. Kreuter J. “Nanoparticles-a historical perspective”. International Journal of Phytomedicine 331 (2007): 1-10.
29. De Jong WH and Borm PJ. “Drug delivery and nanoparticles: applications and hazards”. International Journal of Nanomedicine 3 (2008): 133-149.
30. Cho K., et al. “Therapeutic nanoparticles for drug delivery in cancer”. Clinical Cancer Research 14 (2008): 1310-1316.
31. Ibrahim WM., et al. “Novel sulpiride-loaded solid lipid nanoparticles with enhanced intestinal permeability”. International Journal of Nanomedicine 9 (2014): 129-144.
32. Martín AR., et al. “The effects of resveratrol, a phytoalexin derived from red wines, on chronic inflammation induced in an experimentally induced colitis model”. British Journal of Pharmacology 147 (2006): 873-885.
33. Cianciulli A., et al. “Modulation of NF-κB activation by resveratrol in LPS treated human intestinal cells results in downregulation of PGE2 production and COX-2 expression”. Toxicology In Vitro 26 (2012): 1122-1128.
34. Hussein MA., et al. “Resveratrol nanoemulsion; a promising protector against Ethinylestradiol-induced Hepatic Cholestasis in Female Rats”. Journal of Biomolecular Research and Therapeutics 8 (2019): 175-183.
35. Maxwell JR., et al. “Methods of Inducing Inflammatory Bowel Disease in Mice”. Current Protocols in Pharmacology Chapter 5 (2009): Unit 5.58.
36. Nagib MM., et al. “Anti-inflammatory and anti-oxidant activities of olmesartan medoxomil ameliorate experimental colitis in rat”. Toxicology and Applied Pharmacology 271 (2013): 106-113.
37. Okhawa H., et al. “Assay of lipid peroxides in animal tissues by thiobarbituric acid reaction”. Analytical Biochemistry 95 (1979): 351.
38. Sedlak J., et al. “Estimation of total protein bound and non-protein sulfhydryl groups in tissue with Ellmans reagent”. Analytical Biochemistry 25 (1968): 293-298.
39. Misra HP and Fridovich I. “The role of superoxide anion in the autooxidation of epinephrine anion in the autooxidation of epinephrine and a simple assay of superoxide dismutase”. Journal of Biological Chemistry 247 (1972): 3170.
40. , et al. “Hypocatalasemia, a new genetic carrier state”. Journal of Clinical Investigation 29 (1960): 610-616.
41. Kawakami M., et al. “Measurement of interleukin-6, interleukin-10, and tumor necrosis factor-alpha levels in tissues and plasma after thermal injury in mice”. Surgery 121 (1997): 440.
42. Miranda KM., et al. “A rapid, simple spectrophotometric method for simultaneous detection of nitrate and nitrite”. Nitric Oxide 5 (2001) 62-71.
43. El-Ashmawy N., et al. “Roflumilast, type 4 phosphodiesterase inhibitor, attenuates inflammation in rats with ulcerative colitis via down-regulation of iNOS and elevation of Camp”. International Immunopharmacology 56 (2018): 36-42.
44. Krawisz J., et al. “Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity: Assessment of inflammation in rat and hamster models”. Gastroenterology 87 (1984): 1344 -1350.
45. Lowry O., et al. “Protein measurement with the folin phenol reagent”. Journal of Biological Chemistry 19 (1951)3: 265-275.
46. Sanchez-Munoz, F., et al. “Role of cytokines in inflammatory bowel disease”. World Journal of Gastroenterology 14 (2008): 4280-4288.
47. Abdel-Maksoud H., et al. “Cranberry extract as a functional food in treatment of myocardial toxicity induced by nicotine in Rats”. International Journal of Pharma Sciences4 (2015): 1174-1180.
48. Ali HA., et al. “Biochemical effect of cranberry extract on experimentally induced myocardial infarction”. Benha Veterinary Medical Journal1 (2017): 59-66.
49. Hassan SA., et al. “Protective Effect of Cranberry Extracts against Oxidative Stress and DNA Damage Induced by Diclofenac Sodium in Kidney of Male Albino Rate”. Chinese Medicine 8 (2017): 113-131.
50. El-gizawy A., et al. “Chemical Composition of the Essential oil of the Leaves of Pimenta diocia (L.) Merr. and Pimenta racemosa (Mill.) cultivated in Egypt and evaluation of their in-vitro antioxidant and antidiabetic”. International Journal of Phytomedicine 4 (2018): 226-234.
51. Hussein MA. “Cardioprotective effects of astaxanthin against isoproterenol-induced cardiotoxicity in rats”. Journal of Nutrition and Food Sciences 5 (2015): 1-6.
52. Hussein MA. “Purslane Extract Effects on Obesity-Induced Diabetic Rats Fed a High-Fat Diet”. Malaysian Journal of Nutrition 3 (2010): 419-429.

Citation

Citation: Mohammed A Hussein., et al. “Resveratrol Nanoemulsion; A Promising regulator of TGFB1and TFF-3 Genes Expression in DSS-Induced Ulcerative Colitis in Rats".Acta Scientific Nutritional Health 5.2 (2021): 18-29.

Copyright

Copyright: © 2021 Mohammed A Hussein., et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.